Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DBH | P09172 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.31 |
| ▸ | TUBB | P07437 | 2/20 | 0.31 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.31 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.31 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.31 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.31 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.31 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.31 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.31 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.31 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308499 | 0.83 | HTR2C (0.40) | HTR2CDBHPRMT5TUBB4ATUBB | |
| SCHEMBL7958454 | 0.78 | HTR2C (0.60) | HTR2CKDRFLT3GSK3BUSP2 | |
| SCHEMBL308890 | 0.74 | HTR2C (0.33) | HTR2CDBH | |
| SCHEMBL308399 | 0.74 | IDO1 (0.33) | — | |
| SCHEMBL308174 | 0.72 | HTR2C (0.33) | HTR2C | |
| SCHEMBL733368 | 0.68 | FGFR1 (0.40) | MAPK1HTTNPC1ALDH1A1HPGD | |
| SCHEMBL308897 | 0.68 | PIP4K2A (0.36) | HTR2CHTTALDH1A1 | |
| SCHEMBL24968817 | 0.67 | MAPT (0.36) | HTR2CTSHRHTTLMNA | |
| SCHEMBL12992798 | 0.67 | DBH (0.35) | HTR2CMAPK1DBHALDH1A1LMNA | |
| SCHEMBL1450339 | 0.66 | CDK4 (0.41) | HTR2CMAPK1TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111406-B1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK SHARP & DOHME (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8093389-B2 | e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases | MERCK SHARP & DOHME CORP. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2111406-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | Merck & Co., Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008088688-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171761-A1 | Substituted spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171761-A1 | Substituted spirochromanone derivatives | CBR3, CBR1, CNKSR1 | HTR2C 758/4885KDR 1932/4885FLT3 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.